| 程鹏玲 于春丽 宋闰宇 张玉波 刘振坤.依达拉奉联合醒脑静治疗急性脑出血的临床疗效观察[J].,2016,16(4):751-754 |
| 依达拉奉联合醒脑静治疗急性脑出血的临床疗效观察 |
| Edaravone plus Xingnaojing for Patients with Acute Cerebral Hemorrhage |
| |
| DOI： |
| 中文关键词: 急性脑出血 依达拉奉 醒脑静 |
| 英文关键词: cerebral hemorrhage Edaravone Xingnaojing |
| 基金项目: |
|
| 摘要点击次数: 542 |
| 全文下载次数: 0 |
| 中文摘要: |
| 目的：探究依达拉奉联合醒脑静治疗急性脑出血（ACH）的临床疗效及对炎症指标的影响。方法：本研究于2013 年2 月
~2015 年2 月期间，选择我院收治的ACH患者128 例为研究对象，采用随机数字法将其分为研究组（65 例）和对照组（63 例）。两
组患者均给予一般常规治疗并给予依达拉奉，研究组患者在此基础上联用醒脑静注射液治疗。观察两组患者治疗前后炎症因子
变化、采用美国国立卫生研究院的卒中量表（NIHSS）评价神经功能缺损修复情况、采用格拉斯哥昏迷评分（GCS）评价患者意识状
态，并对比治疗后临床疗效。结果：治疗后两组患者C反应蛋白（CRP）、肿瘤坏死因子-alpha（TNF-alpha）、白介素-6（IL-6）水平和NIHSS
评分均出现明显降低（均P<0.05），GCS评分均出现明显升高（P<0.05），且研究组上述指标改善均优于对照组，差异均存在统计学
差异（均P<0.05）；治疗后研究组有效率为87.69%，显著高于对照组的69.84%（X2=6.125，P=0.013）。结论：依达拉奉联合醒脑静治
疗ACH，能够改善患者神经功能损伤及炎症反应，预后好，疗效确切，具有重要的临床价值。 |
| 英文摘要: |
| Objective:To explore the clinical efficacy of edaravone combined with Xingnaojing in the treatment of patients with
acute cerebral hemorrhage (ACH) and its influence on inflammation factors.Methods:A total of 128 patients with ACH, who were
admitted to Zhuozhou Hospital fromFebruary 2013 to February 2015, were selected and randomly divided into research group(n=65) and
control group (n=63). The two groups were treated with conventional therapy plus edaravone, on the basis of which the research group
was added Xingnaojing injection. The changes of inflammatory factors in the two groups were observed before and after treatment, the
nerve function defects were evaluated by National Institute of Health stroke scale (NIHSS) score, and the state of consciousness was
evaluated by glasgow coma scale(GCS) score. Finally the clinical efficacy was compared after treatment between the two groups.Results:The levels of CRP, TNF-alpha, IL-6 and NIHSS score significantly declined and GCS score significantly increased in the two groups after
treatment compared with before treatment (P<0.05), in addition, the above indexes in the research group were improved more
significantly than those in the control group, the differences were statistically significant (P<0.05). The effective rate (87.69%) in the
research group was significantly higher than that (69.84%) in the control group (x2=6.125, P=6.125).Conclusion:Edaravone combined
with Xingnaojing can effectively improve the nerve function defects and inflammation reaction in the treatment of patients with ACH,
with good prognosis and definite clinical efficacy, which has an important clinical value. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
